Similarly, in another randomized trial,15 128 patients with advanced cholangiocarcinoma underwent standard chemotherapy in combination with the PD‐L1 inhibitor, either with or without the CTLA4 inhibitor. This evidence concerns the gene CTLA4 and cholangiocarcinoma.